RT Journal Article
SR Electronic
T1 Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21259226
DO 10.1101/2021.07.06.21259226
A1 Melani, Rafael D.
A1 Soye, Benjamin J. Des
A1 Kafader, Jared O.
A1 Forte, Eleonora
A1 Hollas, Michael
A1 Blagojevic, Voislav
A1 Negrão, Fernanda
A1 McGee, John P.
A1 Drown, Bryon
A1 Lloyd-Jones, Cameron
A1 Seckler, Henrique S.
A1 Camarillo, Jeannie M.
A1 Compton, Philip D.
A1 LeDuc, Richard D.
A1 Early, Bryan
A1 Fellers, Ryan T.
A1 Cho, Byoung-Kyu
A1 Mattamana, Basil Baby
A1 Goo, Young Ah
A1 Thomas, Paul M.
A1 Ash, Michelle K.
A1 Bhimalli, Pavan P.
A1 Al-Harthi, Lena
A1 Sha, Beverly E.
A1 Schneider, Jeffrey R.
A1 Kelleher, Neil L.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259226.abstract
AB Methods of antibody detection are used to assess exposure or immunity to a pathogen. Here, we present Ig-MS, a novel serological readout that captures the immunoglobulin (Ig) repertoire at molecular resolution, including entire variable regions in Ig light and heavy chains. Ig-MS uses recent advances in protein mass spectrometry (MS) for multi-parametric readout of antibodies, with new metrics like Ion Titer (IT) and Degree of Clonality (DoC) capturing the heterogeneity and relative abundance of individual clones without sequencing of B cells. We apply Ig-MS to plasma from subjects with severe & mild COVID-19, using the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 as the bait for antibody capture. Importantly, we report a new data type for human serology, with compatibility to any recombinant antigen to gauge our immune responses to vaccination, pathogens, or autoimmune disorders.Competing Interest StatementN.L.K., J.O.K., and P.D.C. report a conflict of interest with I2MS technology used to readout the Ig profiles, currently being commercialized by Thermo Fisher Scientific.Funding StatementThis study was funded by: the National Institute of Health under a grant from the National Institute of General Medical Sciences P41 GM108569 (N.L.K.); the Research Corporation (Grant no. 27372, N.L.K. and E.F.); Administrative Supplement to SBIR grant number R44 GM121130 (P.D.C.); Walder Foundation grant number SCI16 (J.R.S.); the NIH Office of Director award S10 OD025194 (P.D.C.); the Northwestern Medicine Dr. Michael M. Abecassis Transplant Innovation Endowment Grant; NCI CCSG P30 CA060553 (awarded to the Robert H. Lurie Comprehensive Cancer Center).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board at Rush University under number 20032502-IRB01 and the final decision for this study was approved. Review board members: Hall, Deborah, MD, PhD (Chair), Neurological Sciences, Rush University Medical Center Simpson, Mindy, PhD (Vice-Chair), Department of Pediatrics, Rush University Medical Center Hallab, Nadim, PhD, Section of Orthopedic Research, Rush University Medical Center Norrington, Geri, Community Member (Non-Scientist) Smith, Mary, MSN, RN-BC, Department of Nursing, Rush University Medical Center Thomason, Clayton, J.D., M.Div, Chaplaincy Services, Rush University Medical Center Mayahara, Masako, RN, PhD, FPCN, CHPN, Communtiy and Mental Health (CON), Rush University Medical Center Bahena, Laura, Community Member (Non-Scientist) Paun, Olimpia, PhD, PMHCNS-BC, College of Nursing, Rush University Medical Center All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed datasets utilized for the IgMS analyses can be found on the MassiVE repository, MSV000087529, after puplication. Custom compiled code used to process and create I2MS files is already available16. Additional desired software and data that support the findings of this study are available from the corresponding authors upon request.